# Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium

> **NCT00310011** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 71 (estimated)

## Conditions studied

- Bladder Cancer
- Transitional Cell Cancer of the Renal Pelvis and Ureter

## Interventions

- **DRUG:** cisplatin
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** paclitaxel
- **PROCEDURE:** conventional surgery

## Key facts

- **NCT ID:** NCT00310011
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-06
- **Primary completion:** 2005-10
- **Final completion:** 2009-08
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2018-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00310011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00310011, "Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00310011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*